You are currently viewing a new version of our website. To view the old version click .
International Journal of Molecular Sciences
  • Concept Paper
  • Open Access

2 May 2023

A New Unified Theory of Trigger Point Formation: Failure of Pre- and Post-Synaptic Feedback Control Mechanisms

Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
This article belongs to the Special Issue The Physical, Molecular, and Cellular Basis of Neuromuscular Nociplastic Pain

Abstract

The origin of the myofascial trigger point (TrP), an anomalous locus in muscle, has never been well-described. A new trigger point hypothesis (the new hypothesis) presented here addresses this lack. The new hypothesis is based on the concept that existing myoprotective feedback mechanisms that respond to muscle overactivity, low levels of adenosine triphosphate, (ATP) or a low pH, fail to protect muscle in certain circumstances, such as intense muscle activity, resulting in an abnormal accumulation of intracellular Ca2+, persistent actin-myosin cross bridging, and then activation of the nociceptive system, resulting in the formation of a trigger point. The relevant protective feedback mechanisms include pre- and postsynaptic sympathetic nervous system modulation, modulators of acetylcholine release at the neuromuscular junction, and mutations/variants or post-translational functional alterations in either of two ion channelopathies, the ryanodine receptor and the potassium-ATP ion channel, both of which exist in multiple mutation states that up- or downregulate ion channel function. The concepts that are central to the origin of at least some TrPs are the failure of protective feedback mechanisms and/or of certain ion channelopathies that are new concepts in relation to myofascial trigger points.

1. Introduction

The myofascial trigger point (TrP), considered to be the underlying cause of myofascial pain syndromes, was described by Travell and Rinzler in 1946 [1]. It has been increasingly studied since, despite a controversy over its existence [2]. Clinical presentations and management regimens are well-represented in the literature, but there has been little or no discussion of its origin. This paper proposes a new hypothesis of trigger point formation, one that has not appeared in the literature previously. It is acknowledged that there may be multiple causes for TrP formation [3], all leading to a same result, the TrP, and that the mechanisms proposed here may apply only to a subset of TrPs.
The specific mechanisms by which the TrP develops remains unknown despite descriptions of mechanical and physiologic stresses that are predisposed to and maintain the TrP, such as the perpetuating factors identified by Travell and Simons [4]. Simons proposed an integrated TrP hypothesis that implicated an energy crisis as a major factor causing TrPs. His hypothesis, based on (1) the absence of motor action potentials, (2) the activation of TrPs by muscle overload, (3) nociceptor activation, and (4) the therapeutic effect of stretching, postulated an overactive neuromuscular junction (NMJ) that releases excessive acetylcholine (ACh) in response to muscle overload ([4] pp. 68–79). He further postulated that the capillary compression from TrPs leads to ischemia and an inability to replenish adenosine triphosphate (ATP) that prevents the reuptake of Ca2+ from the muscle cytosol, resulting in persistent muscle sarcomere contractions. The integrated hypothesis of Simon, useful as it was, did not in fact address the actual mechanisms by which the TrP is formed. It did not account for the many regulatory mechanisms that protect muscle from injury. Even the updated versions of Simons’ integrated hypothesis left the actual origin of the TrP as a ‘black box’ mystery [5,6]. The new hypothesis proposed here is based on physiologic mechanisms that could play a role in the genesis of the TrP in at least a subset of cases. The new hypothesis is derived from a review of the current literature. It proposes that there is a failure of protective regulatory mechanisms, many of them feedback mechanisms, that prevent excessive muscle activity or that prevent a potentially injurious accumulation of Ca2+ within the muscle cytosol and offers specific examples to support the hypothesis. The new hypothesis relates these mechanisms to the development of the TrP in a way that has not been described in the literature before. It is offered as a means of stimulating research into the physiology of TrP formation and has implications for the nature of unusual fatigue and weakness in muscles with TrPs, as well as treatment implications.
Myofascial TrPs were described about 75 years ago in a paper on non-cardiac chest pains [1], though there were descriptions of similar phenomena prior to that time. Subsequent publications described referred to pain patterns and the effect of manual or invasive therapy (dry needling or TrP injection). Early histopathological reports of muscle hardening or myogelosis in TrP regions found focal areas of swelling in muscle [7,8,9,10]. Electrophysiologic studies of the TrP began to be published in the 1990s [11,12,13]. A microanalytic technique that explored the extracellular biochemical milieu of the TrP opened a new means of investigation [14]. TrP imaging, long an elusive goal, is accomplished by magnetic resonance elastography [15] and high-definition ultrasound [16]. Histopathological studies of TrPs in humans remains sparse but suggests that segmental sarcomere contraction occurs at the TrP or in adjacent taut bands (TB) [17,18].

2. Trigger Point Physiology

This section summarizes the present body of evidence for TrP physiology, imaging, and structure, and suggests some implications of the findings (Table 1).

2.1. Electrophysiology

Normal resting muscle is relatively electrically quiet. Miniature endplate potentials (MEPPs) occur at a frequency of 1–6 per second and endplate spikes occur in resting muscle [19,20]. In contrast to resting muscle, the electromyogram (EMG) of the TrP shows a persistent, low amplitude (5–50 µV), high frequency activity that looks like high frequency MEPPs punctuated by intermittent, higher amplitude (100–600 µV), that are initially negative, biphasic, endplate spikes [13]. Resting TrP EMG activity, termed endplate noise (EPN), may be as much as two to three orders of magnitude faster than normal MEPP frequency. EPN indicates that there is an excess of ACh molecules at the NMJ endplate zone in TrPs compared to normal resting muscle, suggesting that there might be a failure of the feedback mechanisms that regulate the release of ACh from the MNT. Alpha-adrenergic inhibitors and botulinum toxin both reduce EPN activity [12,13,21], indicating that EPN is the result of ACh released from presynaptic vesicles.

2.2. Sympathetic Nerve Inhibition of TrP EPN

The ⍺-adrenergic inhibitor phentolamine reduces the average integrated signal of EPN by about 60% [13], but the specific mechanism by which this occurs has not been previously addressed. Both the ⍺- and β-sympathetic nervous systems play a role in modulating muscle contraction, as will be discussed subsequently.

2.3. Biochemical Pathophysiology

The TrP extracellular milieu is acidic (pH in the range of 4–5, below the normal range of 7.35–7.45) and has elevated levels of cytokines and neurotransmitters, such as IL-6, bradykinin, substance P, and calcitonin-gene-related-peptide (CGRP) compared to non-trigger point regions [14]. The acidic pH suggests that the TrP region is hypoxic and ischemic [20]. An acid extracellular milieu can inhibit acetylcholinesterase (AChE), and therefore can contribute to an increase in the concentration of ACh molecules at the motor endplate. CGRP can increase the quantal size of ACh released from the motor nerve terminal [22] and can upregulate nicotinic ACh receptors (nAChRs) at the motor endplate region, thereby expanding the AChR zone [23]. Thus, CGRP co-released with ACh from the MNT has the effect of increasing the number of ACh molecules at the motor end plate [24]. The CGRP effect at the NMJ is delayed, though not immediately, but it could be an upstream initiating event contributing to the development of the TrP.
Neurotransmitters and cytokines present in high concentration in the extracellular TrP milieu, such as substance P and CGRP may also produce neurogenic edema. The hypoechoic appearance of the TB on high-definition ultrasound is consistent with neurogenic edema, although there are other explanations for the nodular swelling at the TrP, including the recent finding of glycosaminoglycans surrounding contraction knots in an experimental TrP paradigm [25,26,27,28,29]. These possible causes of the stiffened taut band differ from the long-held idea that the taut band is the result of multiple short loci of contracted sarcomeres alternating with long zones of stretched sarcomeres.

2.4. Histopathological Evidence

Segmental sarcomere contraction was found retrospectively in one canine skeletal muscle specimen obtained by open biopsy from a taut band [18], and has been reported in one study of human trapezius muscle obtained by needle biopsy of a TrP region [17] performed for a study of other aspects of muscle morphology. The term ‘contraction knots’ has been used both to describe the regions of segmental sarcomere contraction and the palpable nodular hardness found within the TB ([4] pp. 67–69).
Segmental sarcomere contraction has been reported in two different animal models designed to replicate the TrP phenomenon [27,28,29]. One model utilized blunt trauma to the muscle followed by intensive exercise. The other used AChE inhibitors to induce segmental sarcomere shortening and other TrP phenomena. In addition, muscle fiber super-contraction associated with large intracellular increases in unstimulated Ca2+ was found in KATP-deficient mouse flexor digitorum brevis single muscle fibers that were exercised to fatigue [30].
Sarcomere hypercontraction can be seen as an artifact in percutaneous muscle biopsy specimens, but this artifact does not occur when the specimens are treated with osmolarity-corrected glutaraldehyde [31], as was carried out in the study reporting on segmental sarcomere contraction in humans [17]. Anesthetics, such as lidocaine and bupivacaine can result in muscle degeneration and hypercontraction. Open biopsies are generally length-fixed and do not show segmental hypercontraction. The segmental hypercontraction in the human biopsy material cited above [17] was seen on material obtained by large bore needle biopsy, but was present both in light microscopic sections and on electron microscopy, the latter was seen in tissue fixed with osmolarity-controlled glutaraldehyde. Segmental sarcomere hypercontraction was also found in a skeletal muscle subjected to eccentrically challenged, unloaded rat adductor longus muscle [32], muscle subjected to repetitive eccentric contractions [33], and in muscle subjected to contraction and tension loading [34,35], studied both by light and electron microscopy.

2.5. Ultrasound Imaging of Trigger Points

Trigger points and TBs appear as hypoechoic regions on ultrasound, with retrograde blood flow seen in the TrP region itself, consistent with ischemia and consequent hypoxia [16].
Table 1. Objective laboratory features and subjective clinical signs of the trigger point upon which the new hypothesis is based. Specificity and sensitivity levels under physical examination are estimates, not from studies.
Table 1. Objective laboratory features and subjective clinical signs of the trigger point upon which the new hypothesis is based. Specificity and sensitivity levels under physical examination are estimates, not from studies.
FeatureDescriptionReferencesLevel of Confidence
ElectrophysiologyHigh frequency, low voltage endplate noise, attenuated by ⍺-adrenergic inhibitors and by botulinum toxin.
  • Eighteen rabbits, 10 received one dose of botulinum toxinTx, 10 received multiple doses of botulinum toxin. Ten were controls. Endplate noise was diminished in all rabbits that received BTx, but not in the control rabbits [21].
  • Spontaneous electrical activity was found in TrPs of 29 tension headache patients, 25 fibromyalgia patients, but in none of the eight controls [11].
  • Phentolamine IV injection vs control injection of saline in nine rabbits. Twenty-five active trigger spot loci were sampled. Mean average integrated signal of spontaneous electrical activity was reduced from 9.89 µV to 9.92 µV (p < 0.05) [13].
[11,13,21]High
HistopathologySegmental sarcomere contraction.
1.32 female office workers, 15 myalgic, and 15 no pain. Taut bands were found in all subjects. Sarcomere compression in five non-myaglic and two myalgic subjects on limited tissue saved from a prior study [17].
1. Canine taut band study, 10 animals, one example identified retrospectively [20].
2.
[17,20,23,29]Probable, not proven
Microanalytic biochemistryAcidic (low pH); elevated levels of certain neurotransmitters and cytokines. Study of humans with neck pain.
Three controls (three latent TrPs, 3 active TrPs, no neck pain, and no TrP). Significantly elevated levels of the following in the active TrP neck pain group (p < 0.01): protons, BDKN, CGRP, Subs P, TNF-alpha, IL-1 beta, 5-HT, NE.
[14]Highly likely; needs confirmation from a second laboratory
Ultrasound imagingNine subjects (seven women), 13 active TrP sites and nine latent TrPs sites. Fourteen normal in trapezius muscles; findings: focal, hypoechoic regions on 2D US and focal regions of reduced vibration amplitude on VSE indicating a localized, stiff nodule.[16]High
Magnetic Resonance ElastographyProof of concept pilot trial on two female subjects showed taut bands that are detectable and quantifiable with MRE imaging. The findings in the subjects suggest that the stiffness of the taut bands (9.0+/−0.9 KPa) may be 50% greater than that of the surrounding muscle tissue.[15]High
Physical examinationTaut band, nodular region of tenderness, reproduction of usual pain; high specificity because a tender nodule on a taut band defines a trigger point.
The outcome of the physical examination of trigger points remains controversial.
[4]Moderate for diagnostic purposes; high specificity, moderate sensitivity
Physical examinationNon-wasting weakness of muscle rapidly reversed after trigger point inactivation, highly specific because improvement after release of a trigger point defines a trigger point effect. There are no studies evaluating this response.[4]N/A; moderate sensitivity, highly specific
HistoryOnset is often preceded by acute or repetitive muscle overuse.[4,6]n/a
Abbreviations: TrP trigger point; BDKN bradykinin; CGRP calcitonin gene-related peptide; Subs P substance P; 5-HT serotonin; NE norepinephrine; US ultrasound; VSE vibration sonoelastography.

4. Conclusions

The new hypothesis proposes that in at least a subset of situations in which TrPs form the initiating event is either an acute muscle overload or repetitive muscle action to fatigue in which muscle activity performed beyond the sustainable capacity of the muscle results in either an excess of ACh molecules at the motor endplate or a dangerously high concentration of Ca2+ in the muscle cytosol or both. In either case, there is a potential danger of muscle injury or damage. The new hypothesis postulates that there are feedback mechanisms both at the presynaptic and the postsynaptic levels to prevent either a consequent dangerous drop in levels of ATP or a dangerous rise in intracellular calcium levels, and that one or more of the myoprotective feedback mechanisms fail.
The new hypothesis suggests areas of productive research and potential management regimens that could be explored. For example, genetic studies of individuals with persistent or recurrent myofascial trigger point pain syndromes could identify ion channelopathies, that could lead to simple treatment measures, such as the avoidance of caffeine, or employ alpha or beta blockers, CGRP inhibitors, or modified exercise regimens. Furthermore, studies of fatiguability in TrP-containing muscles could explain some clinical features of TrPs.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Travel, J.; Rinzler, S. Relief of cardiac pain by local block of somatic trigger areas. Proc. Soc. Exp. Biol. Med. 1946, LXIII, 480–482. [Google Scholar] [CrossRef]
  2. Quintner, J.L.; Bove, G.M.; Cohen, M.L. A critical evaluation of the trigger point phenomenon. Rheumatology 2015, 54, 392–399. [Google Scholar] [CrossRef]
  3. Jafri, M.S. Mechanisms of Myofascial Pain. Int. Sch. Res. Not. 2014, 2014, 523924. [Google Scholar] [CrossRef]
  4. Simons, D.G.; Travell, J.G.; Simons, L. Myofascial Pain and Dysfunction: The Trigger Point Manual, 2nd ed.; Williams and Wilkins: Baltimore, MA, USA, 1999; pp. 69–78. [Google Scholar]
  5. Gerwin, R.D.; Dommerholt, J.; Shah, J.P. An expansion of Simons’ integrated hypothesis of trigger point formation. Curr. Pain Headache Rep. 2004, 8, 468–475. [Google Scholar] [CrossRef]
  6. Bron, C.; Dommerholt, J. Etiology of myofascial trigger points. Curr. Pain Headache Rep. 2012, 16, 439–444. [Google Scholar] [CrossRef]
  7. Glogowsi, G.; Wallraff, J. Ein beitrag zur Klinik und histologie der muskelhärten (myogelosen). Z Orthop. 1951, 80, 237–268. [Google Scholar]
  8. Miehlke, K.; Schulze, G.; Eger, W. Klinishe und experimentelle untersuchungen zum fibrositissyndrom. Z Rheumaforsch 1960, 19, 310–330. [Google Scholar]
  9. Reitinger, A.; Radner, H.; Tilscher, H.; Hanna, M.; Windisch, A.; Feigl, W. Morphologische Untersuchung an Trigger-punkten. Man. Med. 1996, 34, 256–262. [Google Scholar]
  10. Windisch, A.; Reitinger, A.; Traxler, H.; Radner, H.; Neumayer, C.; Feigl, W.; Firbas, W. Morphology and histochemistry of myogelosis. Clin. Anat. 1999, 12, 266–271. [Google Scholar] [CrossRef]
  11. Hubbard, D.R.; Berkoff, G.M. Myofascial trigger points show spontaneous needle EMG activity. Spine 1993, 18, 1803–1807. [Google Scholar] [CrossRef] [PubMed]
  12. Simons, D.G.; Hong, C.A.; Simons, L.S. Prevalence of spontaneous electrical activity at trigger spots and control sites in rabbit muscle. J. Musculoske Pain 1995, 3, 35–48. [Google Scholar] [CrossRef]
  13. Chen, J.T.; Chen, S.M.; Kuan, T.S.; Chung, K.C.; Hong, C.Z. Phentolamine effect on the spontaneous electrical activity of active loci in a myofascial trigger spot of rabbit skeletal muscle. Arch. Phys. Med. Rehabil. 1998, 79, 790–794. [Google Scholar] [CrossRef] [PubMed]
  14. Shah, J.; Phillips, T.M.; Danoff, J.V.; Gerber, L.H. An in vivo microanalytic technique for measuring the local biochemical milieu of human skeletal muscle. J. Appl. Physiol. 2005, 99, 1977–1984. [Google Scholar] [CrossRef] [PubMed]
  15. Chen, Q.; Bensamoun, S.; Basford, J.R.; Thompson, J.M.; An, K.N. Identification and quantification of myofascial taut bands with magnetic resonance elastography. Arch Phys. Med. Rehabil. 2007, 88, 1658–1661. [Google Scholar] [PubMed]
  16. Sikdar, S.; Shah, J.P.; Gebreab, T.; Yen, R.H.; Gillliams, E.; Danoff, J.; Gerber, L.H. Novel applications of ultrasound technology to visualize and characterize myofascial trigger points and surrounding soft tissue. Arch. Phys. Med. Rehabil. 2009, 90, 1829–1838. [Google Scholar] [CrossRef] [PubMed]
  17. Gerwin, R.D.; Cagnie, B.; Petrovic, M.; Van Dorpe, J.; Calders, P.; De Meulemeester, K. Foci of segmentally contracted sarcomeres in trapezius muscle biopsy specimens in myalgic and nonmyalgic human subjects:preliminary results. Pain Med. 2020, 21, 2348–2356. [Google Scholar] [CrossRef] [PubMed]
  18. Simons, D.G.; Stolov, W.C. Microscopic features and transient contraction of palpable bands in canine muscle. Am. J. Phys. Med. 1976, 55, 65–88. [Google Scholar] [PubMed]
  19. Liley, A.W. An investigation of spontaneous activity at the neuromuscular junction of the rat. J. Physiol. 1956, 132, 650–666. [Google Scholar]
  20. Vyskočil, F.; Malomouzh, A.I.; Nikolsky, E.E. Non-quantal acetylcholine release at the neuromuscular junction. Physiol. Res. 2009, 58, 763–784. [Google Scholar] [CrossRef]
  21. Kuan, T.S.; Chen, J.T.; Chen, S.M.; Chien, C.H.; Hong, C.Z. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am. J. Phys. Med. Rehabil. 2002, 81, 512–520. [Google Scholar] [CrossRef]
  22. Barie, P.S.; Mullins, R.J. Experimental methods in the pathogenesis of limb ischemia. J. Surg. Res. 1988, 44, 284–307. [Google Scholar] [CrossRef] [PubMed]
  23. Bogacheva, P.; Balezina, O. Delayed increase of acetylcholine quantal size induced by the activity-dependent release of endogenous CGRP but not ATP in neuromuscular junctions. Synapse 2020, 74, e22175. [Google Scholar] [CrossRef] [PubMed]
  24. Buffelli, M.; Pasino, E.; Cangiano, A. In vivo acetylcholine receptor expression induced by calcitonin generelated peptide in rat soleus muscle. Neuroscience 2001, 104, 561–567. [Google Scholar] [CrossRef] [PubMed]
  25. Sikdar, S. Personal Communication, 2022.
  26. Dommerholt, J.; Gerwin, R.D. Contracture knots vs. trigger points. Comment on Ball et al. Ultrasound confirmation of the multiple loci hypothesis of the myofascial trigger point and the diagnostic importance of specificity in the elicitation of the local twitch response. Diagnostics 2022, 12, 2365. [Google Scholar] [CrossRef] [PubMed]
  27. Zhang, H.; Lü, J.J.; Huang, Q.M.; Liu, L.; Liu, Q.G.; Eric, O.A. Histopathological nature of myofascial trigger points at different stages of recovery from injury in a rat model. Acupunct Med. 2017, 35, 445–451. [Google Scholar] [CrossRef] [PubMed]
  28. Liu, Q.G.; Huang, Q.M.; Liu, L.; Nguyen, T.T. Structural and functional abnormalities of motor endplates in rat skeletal model of myofascial trigger spots. Neurosci. Lett. 2019, 711, 134417. [Google Scholar] [CrossRef] [PubMed]
  29. Margalef, R.; Sisquella, M.; Bosque, M.; Romeu, C.; Mayoral, O.; Monterde, S.; Priego, M.; Guerra-Perez, R.; Ortiz, N.; Tomàs, J.; et al. Experimental myofascial trigger point creation in rodents. J. Appl. Physiol. 2019, 126, 160–169. [Google Scholar] [CrossRef] [PubMed]
  30. Cifelli, C.; Bourassa, F.; Gariépy, L.; Banas, K.; Benkhalti, M.; Renaud, J.M. KATP channel deficiency in mouse flexor digitorum brevis causes fibre damage and impairs Ca2+ release and force development during fatigue in vitro. J. Physiol. 2007, 582 (Pt 2), 843–857. [Google Scholar] [CrossRef]
  31. Roth, S.M.; Martel, G.F.; Rogers, M.A. Muscle biopsy and muscle fiber hypercontraction:a brief review. Eur. J. Appl. Physiol. 2000, 83, 239–245. [Google Scholar] [CrossRef]
  32. Thompson, J.L.; Balog, E.M.; Fitts, R.H.; Riley, D.A. Five myofribrillar lesion types in eccentrically challenged, unloaded rat adductor lungus muscle—A test model. Anat. Rec. 1999, 254, 39–52. [Google Scholar] [CrossRef]
  33. Fridén, J.; Lieber, R.L. Segmental muscle fiber lesions after repetitive eccentric contractions. Cell Tissue Res. 1998, 293, 165–171. [Google Scholar] [CrossRef]
  34. Matsuura, N.; Kawamata, S.; Ozwaw, J.; Kai, S.; Abiko, S.S. Injury and repair of the soleus muscle after electrical stimulation of the scieatic nerve in the rat. Arch. Histol. Cytol. 2001, 64, 393–400. [Google Scholar] [CrossRef]
  35. Matsuura, N.; Kawamata, S.; Ozawa, J.; Kai, S.; Sakaima, H.; Abiko, S. Comparison of sarcomere alterations after muscle contraction and tension loading in the rat soleus muscle. Anat. Sci. Int. 2002, 77, 169–174. [Google Scholar] [CrossRef]
  36. Zhilyakov, N.; Arkhipov, A.; Malomouzh, A.; Samigullin, D. Activation of neuronal nicotinic receptors inhibits acetylcholine release in the neuromuscular junction by increasing Ca2+ flux through Cav1 channels. Intl. J. Mol. Sci. 2021, 22, 9031. [Google Scholar] [CrossRef]
  37. Weller, B.; Karpati, G.; Carpenter, S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J. Neurol. Sci. 1990, 100, 9–13. [Google Scholar] [CrossRef] [PubMed]
  38. McArdle, A.; Edwards, R.H.; Jackson, M.J. Effects of contractile activity on muscle damage in the dystrophin-deficient mdx mouse. Clin. Sci. 1991, 80, 367–371. [Google Scholar] [CrossRef] [PubMed]
  39. Sacco, P.; Jones, D.A.; Dick, J.R.; Vrbová, G. Contractile properties and susceptibility to exercise-induced damage of normal and mdx mouse tibialis anterior muscle. Clin. Sci. 1992, 82, 227–236. [Google Scholar] [CrossRef]
  40. Petrof, B.J.; Shrager, J.B.; Stedman, H.H.; Kelly, A.M.; Sweeney, H.L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA 1993, 90, 3710–3714. [Google Scholar] [CrossRef] [PubMed]
  41. Decrouy, A.; Renaud, J.M.; Davis, H.L.; Lunde, J.A.; Dickson, G.; Jasmin, B.J. Mini-dystrophin gene transfer in mdx4cv diaphragm muscle fibers increases sarcolemmal stability. Gene Ther. 1997, 4, 401–408. [Google Scholar] [CrossRef]
  42. Cifelli, C.; Boudreault, L.; Gong, B.; Bercier, J.P.; Renaud, J.M. Contractile dysfunctions in ATP-dependent K+ channel-deficient mouse muscle during fatigue involve excessive depolarization and Ca2+ influx through L-type Ca2+ channels. Exp. Physiol. 2008, 93, 1126–1138. [Google Scholar] [CrossRef]
  43. Tyapkina, O.V.; Malomovzh, A.I.; Nurullin, L.F.; Nikulsky, E.E. Quantal and non-quantal acetylcholine release at neuromuscular junctions of muscles of different types in a model of hypogravity. Dokl. Biol. Sci. 2013, 448, 4–6. [Google Scholar] [CrossRef]
  44. Nassenstein, C.; Wiegand, S.; Lips, K.J.; Li, G.; Klein, J.; Kummer, W. Cholinergic activation of the murine trachealis muscle via non-vesicular acetylcholine release involving low-affinity choline transporters. Int. Immunopharmacol. 2015, 29, 173–180. [Google Scholar] [CrossRef]
  45. Wang, X.; McIntosh, J.M.; Rich, M.M. Muscle Nicotinic Acetylcholine Receptors May Mediate Trans-Synaptic Signaling at the Mouse Neuromuscular Junction. J. Neurosci. 2018, 38, 1725–1736. [Google Scholar] [CrossRef] [PubMed]
  46. Capogrossi, M.S.; Houser, S.R.; Bahinski, A.; Lakattam, E.G. Synchronous occurence of spontaneous localized calcium release from the sarcoplasmic reticulum generates action potentials in rat cardiac ventricular myocytes at normal resting membrane potential. Circ. Res. 1987, 61, 498–503. [Google Scholar] [CrossRef] [PubMed]
  47. Rodrigues, A.Z.C.; Wang, Z.M.; Messi, M.L.; Delbono, O. Sympathetics regulate neuromuscular Junction Transmission through TRPV1, P/Q- and N-type Ca2+ channels. Mol. Cell Neurosci. 2019, 95, 59–70. [Google Scholar] [CrossRef] [PubMed]
  48. Rodrigues, A.Z.C.; Messi, M.L.; Wang, Z.M.; Abba, M.C.; Pereyra, A.; Birbrair, A.; Zhang, T.; OMeara, M.; Kwan, P.; Lopez, E.I.; et al. The sympathetic nervous system regulates skeletal muscle motor innervation and acetylcholine receptor stability. Acta Physiol. 2019, 225, e13195. [Google Scholar] [CrossRef]
  49. Khan, M.M.; Lustrino, D.; Silveira, W.A.; Wild, F.; Straka, T.; Issop, Y.; O’Connor, E.; Cox, D.; Reishci, M.; Marquardt, T.; et al. Sympathetic innervation controls homeostasis of neuromuscular junctions in health and disease. Proc. Natl. Acad. Sci. USA 2016, 113, 746–750. [Google Scholar] [CrossRef]
  50. Tsentsevisky, A.; Nurullin, L.; Tyapkina, O.; Bukharaeva, E. Sympathomimetics regulate quantal acetylcholine release at neuromuscular junctions through various types of adrenoreceptors. Mol. Cell Neurosci. 2020, 108, 103550. [Google Scholar] [CrossRef]
  51. Bukharaeva, E.; Khuzakhmetova, V.; Dmitrieva, S.; Tsentsevitsky, A. Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction. Int. J. Mol. Sci. 2021, 22, 4611. [Google Scholar] [CrossRef]
  52. Santafe, M.M.; Priego, M.; Obis, T.; Garcia, N.; Tomás, M.; Lanuza, M.A.; Tomás, J. Adenosine receptors and muscarinic receptors cooperate in acetylcholine release modulation in the neuromuscular synapse. Eur. J. Neurosci. 2015, 42, 1775. [Google Scholar] [CrossRef]
  53. Oliveira, L.; Timóteo, M.A.; Correia-de-Sá, P. Modulation by adenosine of both muscarinic M1-faciliation and M2-inhibition of [3H]-acteylcholine release from the rat motor nerve terminal. Eur. J. Neurosci. 2002, 15, 1728–1736. [Google Scholar] [CrossRef] [PubMed]
  54. Coletti, R. The ischemic model of chronic muscle spasm and pain. Eur. J. Transl. Myol. 2022, 32, 10323. [Google Scholar] [CrossRef] [PubMed]
  55. Hurtado, E.; Cilleros, V.; Nadal, L.; Simó, A.; Obis, T.; Garcia, N.; Santafé, M.M.; Tomàs, M.; Halievski, K.; Jordan, C.L.; et al. Muscle Contraction Regulates BDNF/TrkB Signaling to Modulate Synaptic Function through Presynaptic cPKCα and cPKCβI. Front. Mol. Neurosci. 2017, 10, 147. [Google Scholar] [CrossRef]
  56. Mense, S. Algesic agents exciting muscle nociceptors. Exp. Brain Res. 2009, 196, 89–100. [Google Scholar] [CrossRef]
  57. Ma, J.J.; Mah, T.M.; Wang, L.; Hu, Z. Effect of moxibustion on the expression of microglia and brain-derived neurtophic factor protein in the spinal cord of rats with myofascial pain syndrome. Zhen Ci Yan Jiu 2021, 46, 769–774. (In Chinese) [Google Scholar] [CrossRef]
  58. Jasim, H. Topical review: Salivary biomarkers in chronic muscle pain. Scand J. Pain 2022, 23, 3–13. [Google Scholar] [CrossRef]
  59. Watanabe, D.; Wada, M. Fatigue-induced change in T-system excitability and its major cause in rat fast-twitch skeletal muscle in vivo. J. Physiol. 2020, 598, 5195–5211. [Google Scholar] [CrossRef] [PubMed]
  60. Karatzaferi, C.; de Haan, A.; Ferguson, R.A.; van Mechelen, W.; Sargeant, A. Phosphocreatinine and ATP content in human single muscle fibres before and after maximum dynamic exercise. Pflug. Arch. 2001, 442, 467–474. [Google Scholar] [CrossRef]
  61. Jensen, R.; Nielsen, J.; Ørtenblad, N. Inhibition of glycogenolysis prolongs action potential repriming period and impairs muscle function in rat skeletal muscle. J. Physiol. 2020, 598, 789–803. [Google Scholar] [CrossRef]
  62. Renaud, J.M. Studying t-tubular functionality in mechanically skinned fibres to understand the mechanism of muscle fatigue. J. Physiol. 2020, 598, 4999–5000. [Google Scholar] [CrossRef]
  63. Hildago-Lozano, A.; Fernandez-de-las-Peñas, C.; Calderón-Soto, C.; Domingo-Camera, A.; Madeleine, P.; Arroyo-Morales, M. Elite swimmers with and without unilateral shoulder pain: Mechanical hyperalgesia and active/latent trigger points in neck-shoulder muscles. Scand J. Med. Sci. Sport. 2013, 23, 66–73. [Google Scholar] [CrossRef] [PubMed]
  64. Ortego-Santiago, R.; González-Aguado, Á.J.; Fernández-de-las-Peñas, C.; Cleland, J.A.; de-la-Llave-Rincón, A.I.; Koblanz, M.D.; Plaza-Manzano, G. Pressure Pain hypersensitivity and referred pain from muscle trigger points in elite male wheelchair basketball players. Braz. J. Phys. Ther. 2020, 24, 333–341. [Google Scholar] [CrossRef] [PubMed]
  65. Ceballos-Laites, L.; Medrano-de-la-Fuente, R.; Estébanez-De-Miguel, E.; Moreno-Cerviño, J.; Mingo-Goméz, M.T.; Hernando-Garijo, I.; Jiménez-Del-Barrios, S. Effects of dry needling in teres major muscle in elite handball athletes: A randomized controlled trial. J. Clin. Med. 2021, 10, 4260. [Google Scholar] [CrossRef] [PubMed]
  66. Huang, L.L.; Huang, T.S.; Lin, Y.H.; Huang, C.Y.; Yang, J.L.; Lin, J.J. Effects of upper traapezius myofascial trigger points on scapular kinematics and muscle activation in overhead athletes. J. Hum. Kinet. 2022, 84, 32–42. [Google Scholar] [CrossRef]
  67. Zhang, T.; Chi, S.; Jiang, F.; Zhao, Q.; Xiao, B. A protein interaction mechanism for suppressing the mechanosensitive Piezo channels. Nat. Commun. 2017, 8, 1797. [Google Scholar] [CrossRef]
  68. Scala, R.; Maqoud, F.; Zizzo, N.; Passantino, G.; Mele, A.; Camerino, G.M.; McClenaghan, C.; Harter, T.M.; Nichols, C.G.; Tricarico, D. Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome. Cells 2021, 10, 1791. [Google Scholar] [CrossRef]
  69. Riaza, S.; Kraeva, N.; Hopkins, P.M. Malignant hyperthermia in the post-genomics era: New perspectives on an old concept. Anesthesiology 2018, 128, 168–180. [Google Scholar] [CrossRef]
  70. Beebe, D.; Puram, V.V.; Gajic, S.; Thvagaraian, B.; Belani, K.G. Genetics of malignant hyperthermia: A brief update. J. Anesth. Clin. Pharmacol. 2020, 36, 552–555. [Google Scholar] [CrossRef]
  71. Kaur, H.; Katyal NYelam, A.; Kumar, K.; Srivastava, H.; Govindaraian, R. Malignant hyperthermia. Mo. Med. 2019, 116, 154–159. [Google Scholar]
  72. Ogawa, H.; Kurebayashi, N.; Yamazawa, T.; Murayama, T. Regulatory mechanisms of ryanodine receptor/Ca2+ release channel revealed by recent advancements in structural studies. J. Muscle Res. Cell Motil. 2021, 42, 291–304. [Google Scholar] [CrossRef]
  73. Fitts, R.H. Cellular mechanisms of muscle fatigue. Physiol. Rev. 1994, 74, 49–94. [Google Scholar] [CrossRef] [PubMed]
  74. Mele, A.; Camerino, G.M.; Calzolaro, S.; Cannone, M.; Conte, D.; Tricarico, D. Dual response of the KATP channels to staurosporine: A novel role of SUR2B, SUR1 and Kir6.2 subunits in the regulation of the atrophy in different skeletal muscle phenotypes. Biochem. Pharmacol. 2014, 91, 266–275. [Google Scholar] [CrossRef] [PubMed]
  75. Selvin, D.; Renaud, J.M. Changes in myoplasmic Ca2+ during fatigue differ between FDB fibers, between glibenclamide-exposed and Kir6.2-/- fibers and are further modulated by verapamil. Physiol. Rep. 2015, 3, e12303. [Google Scholar] [CrossRef] [PubMed]
  76. Scott, K.; Benkhalti, M.; Calvert, N.D.; Paquette, M.; Zhen, L.; Harper, M.E.; Al-Dirbashi, O.Y.; Renaud, J.M. KATP channel deficiency in mouse FDB causes an impairment of energy metabolism during fatigue. Am. J. Physiol. Cell Physiol. 2016, 311, C559–C571. [Google Scholar] [CrossRef]
  77. Kissane, R.W.P.; Egginton, S.; Askew, G.N. Regional variation in the mechanical properties and fibre-type composition of the rat extensor digitorum longus muscle. Exp. Physiol. 2018, 103, 111–124. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.